12.4 Resuscitation and Supportive Care: Seizures, Hyperthermia, and Hemodynamic Shock

While targeted antidotes and enhanced elimination are vital therapeutic pillars in clinical toxicology, the overwhelming majority of poisoned patients survive or succumb based entirely on the quality of advanced supportive care and resuscitation. In severe, life-threatening poisonings, toxicological disruption converges upon three critical physiological failure modes: toxic status epilepticus, malignant hyperthermia, and refractory hemodynamic shock. Mastering the specialized resuscitation principles that distinguish toxicological emergencies from standard medical critical care is paramount for the Specialist in Poison Information (CSPI).

---

Toxic Seizures and Status Epilepticus

Toxic-induced seizures account for approximately 10% of all status epilepticus presentations in emergency departments. Unlike idiopathic epilepsy, toxic seizures are triggered by acute biochemical disruptions of central neuronal equilibrium—predominantly loss of GABA-mediated inhibitory tone or excessive excitatory monoaminergic / sodium-channel depolarization.

Neurochemical Classification of Toxic Seizures:
1. GABA Depletion / Synthesis Inhibition:  Isoniazid (INH), Gyromitra mushrooms, Hydrazines
2. GABA-A Receptor Channel Antagonism:      Cicutoxin (Water Hemlock), Organochlorines (Lindane), Picrotoxin
3. Sodium Channel & Monoamine Excitation:  Tricyclic Antidepressants (TCAs), Bupropion, Tramadol, Cocaine
4. Glycine Receptor Antagonism:            Strychnine (Spinal convulsions with preserved sensorium)
5. Cellular Hypoxia & Metabolic Depletion: Cyanide, Carbon Monoxide, Sulfonylurea-induced Hypoglycemia

1. Pharmacological Management Hierarchy

• First-Line Therapy: Intravenous Benzodiazepines: Benzodiazepines are the undisputed first-line agents for all toxic seizures. They bind to the allosteric gamma subunit of the GABA_A receptor, increasing the open frequency of the chloride channel and enhancing endogenous GABA inhibitory neurotransmission.
  • Lorazepam: 0.1 mg/kg IV (typically 2 to 4 mg IV in adults) administered every 3 to 5 minutes.
  • Diazepam: 0.2 mg/kg IV (typically 5 to 10 mg IV in adults) every 3 to 5 minutes.
  • Midazolam: 0.2 mg/kg IM/IV (typically 5 to 10 mg in adults); excellent intramuscular absorption when IV access is not yet established.
• Second-Line Therapy: Barbiturates and Propofol: If seizures persist despite high-dose benzodiazepines (e.g., > 12 to 16 mg of lorazepam):
  • Phenobarbital: 20 mg/kg IV infused at up to 50 mg/min. Unlike benzodiazepines, barbiturates increase the duration of chloride channel opening and, at higher concentrations, directly open GABA_A channels independently of endogenous GABA. This makes phenobarbital exceptionally effective when GABA stores are depleted.
  • Propofol: Rapid-acting GABA_A agonist and NMDA blocker; 1 to 2 mg/kg IV bolus followed by continuous infusion (20 to 100 mcg/kg/min).

2. The Critical Contraindication of Phenytoin

ABSOLUTE CLINICAL RULE: Phenytoin and fosphenytoin are completely ineffective in toxic-induced seizures and are STRICTLY CONTRAINDICATED in overdoses involving sodium-channel blocking xenobiotics (such as tricyclic antidepressants, diphenhydramine, and cocaine).

• Mechanistic Ineffectiveness: Phenytoin acts selectively on voltage-gated neuronal sodium channels, prolonging the inactivated state to suppress high-frequency focal epileptic spikes. It exerts zero action on GABA receptors, glycine receptors, or metabolic cellular respiration. In toxic seizures driven by GABA depletion or monoaminergic storm, phenytoin has zero clinical efficacy in terminating seizures.
• Lethal Cardiac Toxicity: In poisonings involving sodium channel blocking agents (TCAs, cocaine, propoxyphene, diphenhydramine), phenytoin produces additive, synergistic myocardial sodium channel blockade. Administering phenytoin in TCA overdose precipitates widening of the QRS complex, refractory ventricular tachycardia, complete AV block, and asystole.

3. Toxin-Specific Seizure Antidotes

When a specific toxin is responsible, targeted antidotes must be administered immediately alongside benzodiazepines:

• Isoniazid (INH) and Gyromitra Mushrooms: Administer intravenous pyridoxine (vitamin B6) gram-for-gram matching the ingested dose (or 5 g IV push empiric). Replaces the coenzyme necessary for glutamic acid decarboxylase to synthesize GABA.
• Tricyclic Antidepressants (TCAs): Administer sodium bicarbonate (1 to 2 mEq/kg IV push) to overcome myocardial sodium channel blockade, narrow the QRS, and raise serum pH.
• Hypoglycemic Agents (Sulfonylureas, Insulin): Administer 50% dextrose (D50W, 50 mL IV) followed by octreotide for sulfonylureas.
• Organophosphates / Nerve Agents: Administer atropine and pralidoxime (2-PAM); control status epilepticus with high-dose midazolam.

---

Toxic Hyperthermia and Severe Temperature Derangements

Toxic hyperthermia—defined as an elevation in core body temperature exceeding 40.0°C to 41.0°C (104.0°F to 105.8°F)—represents an acute, life-threatening toxicological emergency. At core temperatures exceeding 40.5°C, direct thermal cytotoxicity triggers protein denaturation, cell membrane liquefaction, endothelial injury, disseminated intravascular coagulation (DIC), massive rhabdomyolysis, and multisystem organ failure.

Core Toxic Hyperthermia Syndromes:
Sympathomimetic Storm:    Psychomotor agitation + Peripheral vasoconstriction (Cocaine, Methamphetamine)
Serotonin Syndrome:        Hunter Criteria (Spontaneous/inducible clonus, ocular clonus, tremor, diaphoresis)
Neuroleptic Malignant:     Dopamine D2 blockade ('Lead-pipe' rigidity, hyporeflexia, fever, slow onset)
Malignant Hyperthermia:    Ryanodine receptor defect (Triggered by volatile anesthetics / succinylcholine)
Mitochondrial Uncouplers: Salicylates, 2,4-Dinitrophenol (DNP) (Massive ATP uncoupling; heat without rigidity)

1. Pathophysiological Differentiation of Hyperthermic Syndromes

2. Management Hierarchy: Cooling and Neuromuscular Paralysis

Toxic Hyperthermia Resuscitation Flow:
[Core Temperature > 40.0°C / 104°F Recorded via Indwelling Rectal/Bladder Probe]
                               │
                               ▼
RAPID ACTIVE EXTERNAL COOLING (Evaporative mist + Continuous High-Velocity Fans)
                               │
                               ▼
AGGRESSIVE SEDATION: IV Benzodiazepines (Diazepam 5-10 mg or Lorazepam 2-4 mg q5min)
  (Blunts central agitation, suppresses shivering, terminates seizures)
                               │
                               ▼
IF RIGIDITY, STATUS EPILEPTICUS, OR TEMP > 40.5°C PERSISTS:
  Elective Rapid Sequence Intubation + NON-DEPOLARIZING Neuromuscular Blockade
  (Vecuronium 0.1 mg/kg or Rocuronium 1.0 mg/kg IV)
                               │
                               ▼
TARGET ENDPOINT: Core Temperature Dropped to < 38.5°C (101.3°F) Within 30-45 Minutes

• Evaporative Cooling: The single most efficient, rapid, and non-invasive method of heat dissipation. The patient is stripped naked, sprayed continuously with lukewarm water mist, and exposed to high-velocity circulating fans. Lukewarm water prevents peripheral cutaneous vasoconstriction and shivering, maximizing radiant and evaporative heat loss. Ice packs applied to the axillae and groin provide supplemental conductive cooling.
• THE ABSOLUTE BAN ON ANTIPYRETICS: Antipyretic medications—specifically acetaminophen and NSAIDs (ibuprofen, ketorolac)—are COMPLETELY INEFFECTIVE in toxic hyperthermia. Infectious fevers elevate the hypothalamic set-point via pyrogenic cytokines (IL-1, PGE2). Toxic hyperthermia results from unbridled peripheral muscular thermogenesis, cellular mitochondrial uncoupling, or impaired heat dissipation. Antipyretics do not alter peripheral heat generation and introduce severe hepatotoxicity and nephrotoxicity.
• Chemical Neuromuscular Blockade: When skeletal muscle hyperactivity or severe rigidity drives hyperpyrexia refractory to benzodiazepines, the patient must be paralyzed. Paralyzing skeletal muscle eliminates the motor endplate mechanical work that produces internal heat.
• THE SUCCINYLCHOLINE CONTRAINDICATION: Always use non-depolarizing neuromuscular blockers (rocuronium or vecuronium). Depolarizing neuromuscular blockade with succinylcholine is strictly contraindicated; it provokes massive sarcoplasmic potassium release in patients with underlying rhabdomyolysis (triggering fatal hyperkalemic cardiac arrest) and can trigger malignant hyperthermia.

---

Toxic Hemodynamic Shock and Extracorporeal Support

Toxicological shock is categorized hemodynamically into distributive (vasoplegic) shock and cardiogenic shock.

Hemodynamic Shock Differentiation:
Distributive Shock (Vasoplegia):  Low SVR + Warm Peripheries + Normal/High Initial Cardiac Output
  Etiologies: Phenothiazines, Atypical Antipsychotics, Trazodone, Dihydropyridine CCBs, Sepsis-mimics
  Resuscitation: Balanced Crystalloids (1-2 L) ──► Norepinephrine (First-Line) ──► Vasopressin

Cardiogenic Shock (Pump Failure): Low Cardiac Output + Elevated SVR/CVP + Cold Peripheries + Pulmonary Edema
  Etiologies: Beta-Blockers, Non-Dihydropyridine CCBs (Verapamil, Diltiazem), TCAs, Digoxin, Flecainide
  Resuscitation: Inotropes (Epinephrine) ──► HIET / Calcium / Glucagon ──► VA-ECMO Deployment

1. Distributive Vasoplegic Shock

• Mechanisms: Antagonism of peripheral vascular alpha-1 adrenergic receptors (phenothiazines, trazodone, quetiapine), profound inhibition of vascular L-type calcium channels (amlodipine, nicardipine), or severe metabolic acidemia.
• Resuscitation Strategy:
  1. Administer 1 to 2 liters of balanced isotonic crystalloid (Plasmalyte or Lactated Ringer's). Avoid fluid overload.
  2. If mean arterial pressure remains < 65 mmHg, initiate norepinephrine as the first-line vasopressor. Norepinephrine provides potent alpha-1 vasoconstriction to restore systemic vascular resistance combined with modest beta-1 inotropic support.
  3. If vasoplegia is refractory, add vasopressin (0.03 to 0.04 units/min) as a second-line non-adrenergic vasoconstrictor (acts via vascular V₁ receptors).

2. Cardiogenic Toxic Shock

• Mechanisms: Direct myocardial depression, sinus arrest, advanced atrioventricular nodal blockade, or impaired sarcoplasmic calcium release resulting from beta-blockers, verapamil, diltiazem, or sodium channel blockers.
• Resuscitation Strategy: Fluid boluses must be administered with extreme caution to avoid precipitating pulmonary edema. Vasopressors with pure alpha activity (such as phenylephrine) are contraindicated because they augment cardiac afterload without improving contractility.
  1. Epinephrine: The preferred adrenergic vasoactive infusion for cardiogenic shock. Provides potent beta-1 chronotropy and inotropy combined with alpha-1 vascular tone.
  2. High-Dose Insulin Euglycemia Therapy (HIET): Initiated early (1 unit/kg bolus + 1 to 10 units/kg/hr infusion) to restore myocardial carbohydrate metabolism.
  3. Targeted Inotropes: Dobutamine or milrinone may be cautiously added only if systemic vascular resistance is adequate.

3. Mechanical Circulatory Support: Veno-Arterial ECMO

When toxic cardiogenic shock or malignant ventricular dysrhythmias prove refractory to maximum pharmacological resuscitation, Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) represents the definitive life-saving salvage therapy.

• Core Mechanism: Blood is drained from the right atrium via a large venous cannula, pumped through an external membrane oxygenator, and returned under high arterial pressure into the femoral or carotid artery, completely bypassing the non-functioning heart and lungs.
• The 'Bridge to Recovery / Elimination' Concept: In medical critical care, cardiogenic shock secondary to acute myocardial infarction carries a high mortality because the myocardium is irreversibly infarcted. In toxicology, the myocardium is merely biochemically poisoned, not dead. If VA-ECMO maintains systemic end-organ perfusion for 24 to 72 hours, the liver and kidneys will clear the offending xenobiotic, allowing the stunned myocardium to make a full, complete functional recovery.
• Clinical Indications for Toxicological ECMO: Refractory cardiogenic shock (cardiac index < 1.8 L/min/m², arterial lactate > 8 to 10 mmol/L despite triple vasopressors/inotropes), recurrent refractory ventricular fibrillation / tachycardia, or toxic cardiac arrest (Extracorporeal Cardiopulmonary Resuscitation - ECPR).

---

Resuscitation and Hemodynamic Support Matrix

---

Poison Center Case Scenario: Refractory Bupropion Overdose with Status Epilepticus and Shock

A 22-year-old college student is found unresponsive by roommates surrounded by two empty bottles of extended-release bupropion (bupropion XL 300 mg, total ingested dose: approximately 18 g). On EMS arrival, the patient is in active generalized tonic-clonic status epilepticus. EMS administers 10 mg of intramuscular midazolam with only partial cessation of motor seizure activity. On arrival in the resuscitation bay, vital signs are: heart rate 158 beats/min, blood pressure 72/40 mmHg, respiratory rate 26 breaths/min (intubated), and core rectal temperature 40.8°C (105.4°F). Continuous 12-lead ECG reveals an extreme intraventricular conduction defect with a QRS duration of 172 ms and terminal R wave in aVR.

Specialist in Poison Information Interventions

1. Refractory Status Epilepticus Control: The CSPI cautions that bupropion (a norepinephrine-dopamine reuptake inhibitor) is strongly proconvulsant in overdose and that seizures can recur for many hours with extended-release tablets. The CSPI instructs the emergency team to immediately escalate anticonvulsant therapy with lorazepam 4 mg IV, administer a loading dose of phenobarbital (20 mg/kg IV), and initiate a continuous propofol infusion. The physician is explicitly warned never to administer phenytoin.
2. Immediate Hyperthermia Management: Because core temperature exceeds 40.5°C, immediate active cooling is initiated with continuous evaporative lukewarm water mist and high-velocity fans, combined with ice packs applied to the axillae and groin. Antipyretics are prohibited. Neuromuscular paralysis with rocuronium (1.0 mg/kg IV) is maintained to eliminate skeletal muscle thermogenesis, and continuous EEG monitoring is requested because paralysis hides ongoing seizure activity. Core temperature drops to 38.2°C within 35 minutes.
3. Cardiovascular Collapse and QRS Widening: Bupropion metabolites directly inhibit cardiac voltage-gated sodium channels and gap junction intercellular communication. The CSPI directs:
   • Boluses of hypertonic sodium bicarbonate (100 mEq IV push) repeated to narrow the QRS complex below 120 ms and maintain blood pH between 7.50 and 7.55.
   • Initiation of norepinephrine and epinephrine infusions to restore perfusion pressure.
4. Emergent Mechanical Circulatory Support (VA-ECMO): Two hours into resuscitation, the patient develops refractory cardiogenic shock with an arterial lactate of 14 mmol/L and recurrent bursts of polymorphic ventricular tachycardia. Following the CSPI's guidance, the regional Extracorporeal Life Support team cannulates the femoral vessels and initiates Veno-Arterial ECMO. With organ perfusion secured, bupropion and its active hydroxybupropion metabolites are cleared over 48 hours. The patient is successfully decannulated on hospital day 3 with intact neurological function and discharged home on day 8.